Tumor initiation and progression are the outcomes of a stepwise accumulation of genetic alterations. Among these, gene amplification and aberrant expression of oncogenic proteins, as well as deletion or inactivation of tumor suppressor genes, represent hallmark steps. Mounting evidence collected over the last few years has identified different populations of non-coding RNAs as major players in tumor suppression in almost all cancer types. Elucidating the diverse molecular mechanisms underlying the roles of non-coding RNAs in tumor progression might provide illuminating insights, potentially able to assist improved diagnosis, better staging and effective treatments of human cancers. Here we focus on several groups of tumor suppressor microRNAs, whose downregulation exerts a profound oncologic impact and might be harnessed for the benefit of cancer patients.
Tumor suppressor microRNAs : a novel non-coding alliance against cancer / G. Blandino, F. Fazi, S. Donzelli, M. Kedmi, A. Sas-Chen, P. Muti, S. Strano, Y. Yarden. - In: FEBS LETTERS. - ISSN 0014-5793. - 588:16(2014), pp. 2639-2652.
Tumor suppressor microRNAs : a novel non-coding alliance against cancer
P. MutiConceptualization
;
2014
Abstract
Tumor initiation and progression are the outcomes of a stepwise accumulation of genetic alterations. Among these, gene amplification and aberrant expression of oncogenic proteins, as well as deletion or inactivation of tumor suppressor genes, represent hallmark steps. Mounting evidence collected over the last few years has identified different populations of non-coding RNAs as major players in tumor suppression in almost all cancer types. Elucidating the diverse molecular mechanisms underlying the roles of non-coding RNAs in tumor progression might provide illuminating insights, potentially able to assist improved diagnosis, better staging and effective treatments of human cancers. Here we focus on several groups of tumor suppressor microRNAs, whose downregulation exerts a profound oncologic impact and might be harnessed for the benefit of cancer patients.File | Dimensione | Formato | |
---|---|---|---|
Copia di blandino et al.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
363.02 kB
Formato
Adobe PDF
|
363.02 kB | Adobe PDF | Visualizza/Apri |
Blandino_et_al-2014-FEBS_Letters.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.64 MB
Formato
Adobe PDF
|
1.64 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.